ReviewNutrients2026
Curcumin and Cancer-Related Inflammation.
Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of the adipose-derived Stromal Vascular Fraction (SVF) secretome as an immunomodulator in the treatment of chronic inflammatory diseases through NF-κB and macrophage reprogramming.Molecular biology reports · 2026Review
- Targeted co-delivery of curcumin and TRAIL via engineered extracellular vesicles: a synergistic therapy against resistant cancers.Drug delivery and translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation is a well-established risk factor for cancer progression. This review aims to determine how persistent inflammatory signaling reshapes the tissue microenvironment to favor tumor cell proliferation, survival, and progression. It also discusses the role of cytokines such as IL-6 and TGF-β, reactive oxygen species (ROS), and the transcription factors NF-κB and STAT3 in inflammation and in the tumor microenvironment. Sustained activation of these pathways promotes genomic instability, loss of tumor suppressor gene function, enhanced oncogene expression, and resistance to apoptosis, collectively facilitating malignant transformation and tumor development. The key novelty of this review lies in integrating these interconnected networks with new evidence to clarify how they drive cancer initiation and progression. Furthermore, we discuss the therapeutic potential of plant-derived bioactive compounds, with a particular emphasis on curcumin. Curcumin exhibits significant anti-inflammatory and anticancer effects through inhibition of NF-κB and STAT3 signaling and its downstream targets, thereby attenuating inflammation-driven tumorigenesis. However, its clinical application is limited by poor bioavailability. Finally, this review highlights current strategies to overcome these limitations and future directions for optimizing curcumin-based interventions in inflammation-associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.